ArticleNature structural & molecular biology2020
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature structural & molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 335 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
335citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
335 citing papers in PubMed, 1 synthesis or guideline pooled it, 546 citations in OpenAlex.
- Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review.Analytical biochemistry · 2022Pooled it
- Functional customization of peptide linkers in fusion proteins through multimodal deep learning approach.Synthetic and systems biotechnology · 2026Article
- ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses.Journal of virology · 2026Article
- Structure-Guided Design of Proteomimetics Targeting the SARS-CoV-2 S-RBD/hACE2 Interface.Journal of medicinal chemistry · 2026Article
- Construction of Synthetic Probiotic Bacteria for In Situ Delivery of Anti-SARS-CoV-2 Nanobodies.Probiotics and antimicrobial proteins · 2026Article
- Exploring the diverse binding ability of SARS-CoV-2 variant RBDs to different antibody classes: a computational study.RSC advances · 2026Article
- A Precision-Engineered DC-Targeting mRNA-LNP Neoantigen Vaccine Elicits Stronger T Cell Responses and Exhibits Superior Tumor Control.Vaccines · 2026Article
- Review
- Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation.Military Medical Research · 2026Review
- Anti-SARS-CoV-2 VHH and C7C peptide fused with Angiopep-2 efficiently traverse blood-brain barrier model and neutralizes virus.Frontiers in microbiology · 2026Article
- Engineered bacteria as an orally administered anti-viral treatment and immunization system.Gut microbes · 2025Article
- Review
- Engineering Two-Dimensional Nanobody-Origami Architectures for Enhanced Antiviral Activity.Nano letters · 2025Article
- Article
- Bivalent single-domain antibodies show potent mpox virus neutralization through M1R antigen.Communications biology · 2025Article
- Predicting high-fitness viral protein variants with Bayesian active learning and biophysics.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.Frontiers of medicine · 2025Article
- Insights into the recognition mechanism of shark-derived single-domain antibodies with high affinity and specificity targeting fluoroquinolones.Marine life science & technology · 2025Article
- Small but Mighty: Nanobodies in the Fight Against Infectious Diseases.Biomolecules · 2025Review
- Nanobody engineering: computational modelling and design for biomedical and therapeutic applications.FEBS open bio · 2025Review
275 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
33 authors at 7 institutions in 1 country.
Jiandong HuoStructural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, Didcot, UK.
Audrey Le BasDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Reinis R RuzaDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Helen M E DuyvesteynDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Halina MikolajekDiamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
Tomas MalinauskasDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.ORCID http://orcid.org/0000-0002-4847-5529
Tiong Kit TanMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0001-8746-8308
Pramila RijalMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Maud DumouxStructural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, Didcot, UK.ORCID http://orcid.org/0000-0002-1732-1041
Philip N WardDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.ORCID http://orcid.org/0000-0003-2546-3426
Jingshan RenDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Daming ZhouDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Peter J HarrisonDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Miriam WeckenerStructural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, Didcot, UK.
Daniel K ClareDiamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
Vinod K VogiralaDiamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
Julika RadeckeDiamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
Lucile MoyniéStructural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, Didcot, UK.
Yuguang ZhaoDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.ORCID http://orcid.org/0000-0001-8916-8552
Javier Gilbert-JaramilloSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1268-2304
Michael L KnightSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-8780-1630
Julia A TreeNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Karen R ButtigiegNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Naomi CoombesNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Michael J ElmoreNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Miles W CarrollNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Loic CarriqueDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.ORCID http://orcid.org/0000-0001-5332-8593
Pranav N M ShahDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.ORCID http://orcid.org/0000-0003-1212-904X
William JamesSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2506-1198
Alain R TownsendMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
David I StuartDivision of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.ORCID http://orcid.org/0000-0002-3426-4210
Raymond J OwensStructural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, Didcot, UK. raymond.owens@rc-harwell.ac.uk.
James H NaismithStructural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, Didcot, UK. naismith@strubi.ox.ac.uk.ORCID http://orcid.org/0000-0001-6744-5061
Centre for Human Genetics · GBPublic Health England · GBDiamond Light Source · GBRosalind Franklin Institute · GBUniversity of Oxford · GBAcademy of Medical Sciences · GBJohn Radcliffe Hospital · GB
Funding
Cancer Research UK 26752Medical Research Council G1100525Medical Research Council MR/N00065X/1Medical Research Council MR/V001329/1Medical Research Council MR/V03958X/1Wellcome Trust 100209/Z/12/ZWellcome Trust 101122/Z/13/Z
Abstract
The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a more serious illness than influenza. The SARS-CoV-2 receptor binding domain (RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a prelude to viral entry into the cell. Using a naive llama single-domain antibody library and PCR-based maturation, we have produced two closely related nanobodies, H11-D4 and H11-H4, that bind RBD (K
Indexed as
Coronavirus InfectionsPandemicsPneumonia, ViralAmino Acid SequenceAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralAntibody AffinityAntigen-Antibody ReactionsBetacoronavirusBinding, CompetitiveCOVID-19Cryoelectron MicroscopyCrystallography, X-RayEpitopesHumansACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralEpitopesImmunoglobulin Fc FragmentsPeptide LibraryPeptidyl-Dipeptidase AReceptors, VirusRecombinant Fusion ProteinsSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.